CR10095A - Derivados de pirimidina para el tratamiento del crecimiento celular anormal - Google Patents
Derivados de pirimidina para el tratamiento del crecimiento celular anormalInfo
- Publication number
- CR10095A CR10095A CR10095A CR10095A CR10095A CR 10095 A CR10095 A CR 10095A CR 10095 A CR10095 A CR 10095A CR 10095 A CR10095 A CR 10095A CR 10095 A CR10095 A CR 10095A
- Authority
- CR
- Costa Rica
- Prior art keywords
- treatment
- cellular growth
- abnormal cellular
- pirimidine derivatives
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La presente invención se refiere a un compuesto de fórmula 1 o una sal farmacéuticamente aceptable del mismo, en la que Ar es un grupo de fórmula y R1, R2, R13, A, K, M, L1, L2, X, Y1, Y2, Q, sal del mismo, en la que R1, R2, R13, A, K, L1, L2, W, X, Z, Z2, Y1, Y2, Z1, Z2, M, Q, W, X, m, p, y q son como se han definido en este documento. Dichos nuevos derivados de pirimidina son útiles en el tratamiento del crecimiento celular anormal, tal como cáncer, en mamíferos. Esta invención también se refiere a un procedimiento de uso de dichos compuestos en el tratamiento del crecimiento celular anormal en mamíferos, especialmente seres humanos, y a composiciones farmacéuticas que contienen dichos compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75270805P | 2005-12-21 | 2005-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR10095A true CR10095A (es) | 2008-07-17 |
Family
ID=38038639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR10095A CR10095A (es) | 2005-12-21 | 2008-06-20 | Derivados de pirimidina para el tratamiento del crecimiento celular anormal |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7820648B2 (es) |
| EP (1) | EP1966207A2 (es) |
| JP (1) | JP4332590B2 (es) |
| KR (1) | KR101060051B1 (es) |
| CN (1) | CN101346380B (es) |
| AP (1) | AP2008004488A0 (es) |
| AR (1) | AR058399A1 (es) |
| AU (1) | AU2006327871A1 (es) |
| BR (1) | BRPI0620324A2 (es) |
| CA (1) | CA2634646C (es) |
| CR (1) | CR10095A (es) |
| DO (1) | DOP2006000289A (es) |
| EA (1) | EA014551B1 (es) |
| EC (1) | ECSP088563A (es) |
| GT (1) | GT200600517A (es) |
| HN (1) | HN2006042221A (es) |
| IL (1) | IL191555A0 (es) |
| MA (1) | MA30075B1 (es) |
| ME (1) | MEP0908A (es) |
| NL (1) | NL2000375C2 (es) |
| NO (1) | NO20082338L (es) |
| PE (1) | PE20071138A1 (es) |
| RS (1) | RS20080272A (es) |
| SV (1) | SV2008002969A (es) |
| TN (1) | TNSN08270A1 (es) |
| TW (1) | TW200736258A (es) |
| UA (1) | UA89123C2 (es) |
| UY (1) | UY30051A1 (es) |
| WO (1) | WO2007072158A2 (es) |
| ZA (1) | ZA200804488B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2533377C (en) | 2003-07-30 | 2012-11-27 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
| US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| CA2654670A1 (en) * | 2006-07-06 | 2008-01-10 | Boehringer Ingelheim International Gmbh | New compounds |
| WO2008051547A1 (en) * | 2006-10-23 | 2008-05-02 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
| BRPI0810411B8 (pt) | 2007-04-18 | 2021-05-25 | Pfizer Prod Inc | derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica |
| AU2008275918B2 (en) | 2007-07-17 | 2014-01-30 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as PKC inhibitors |
| EP2231620A1 (en) * | 2007-12-03 | 2010-09-29 | Boehringer Ingelheim International GmbH | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
| JP2011515372A (ja) * | 2008-03-20 | 2011-05-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ピリミジン類の位置選択的製造法 |
| UY31714A (es) * | 2008-03-20 | 2009-11-10 | Boehringer Ingelheim Int | Preparación selectiva de pirimidinas sustituidas |
| MX2010014057A (es) | 2008-06-17 | 2011-03-21 | Astrazeneca Ab | Compuestos de piridina. |
| EP2161259A1 (de) | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide |
| US20110071158A1 (en) * | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
| TW201100441A (en) * | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| JP5539518B2 (ja) | 2009-08-14 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ２−アミノ−５−トリフルオロメチルピリミジン誘導体の位置選択的調製 |
| US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
| US8466155B2 (en) * | 2009-10-02 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Pyrimidines |
| TWI513694B (zh) * | 2010-05-11 | 2015-12-21 | Amgen Inc | 抑制間變性淋巴瘤激酶的嘧啶化合物 |
| JP5607241B2 (ja) | 2010-05-21 | 2014-10-15 | ケミリア・エービー | 新規ピリミジン誘導体 |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| WO2012074951A1 (en) | 2010-11-29 | 2012-06-07 | OSI Pharmaceuticals, LLC | Macrocyclic kinase inhibitors |
| BR112013024378A2 (pt) | 2011-03-24 | 2016-12-13 | Chemilia Ab | novos derivados de pirimidina |
| CN103987708B (zh) | 2011-12-09 | 2016-06-22 | 奇斯药制品公司 | 4-羟基-1,2,3,4-四氢萘-1-基脲的衍生物及其在呼吸道疾病治疗中的用途 |
| JP2015500862A (ja) | 2011-12-23 | 2015-01-08 | セルゾーム リミティッド | キナーゼ阻害剤としてのピリミジン−２，４−ジアミン誘導体 |
| CN103655577A (zh) * | 2012-09-20 | 2014-03-26 | 杨育新 | 一类治疗创伤性脑损伤疾病的化合物及其用途 |
| CN103664957A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| CN105130907B (zh) * | 2015-07-29 | 2018-10-16 | 沈阳药科大学 | 嘧啶类化合物及其用途 |
| DK3484528T3 (da) | 2016-07-18 | 2021-02-15 | Janssen Pharmaceutica Nv | Tau-pet-billeddannelsesligander |
| US20200038513A1 (en) * | 2018-07-26 | 2020-02-06 | Arvinas Operations, Inc. | Modulators of fak proteolysis and associated methods of use |
| CN116981664A (zh) * | 2021-01-07 | 2023-10-31 | 安大略省癌症研究所(Oicr) | 作为nuak激酶的抑制剂的噻吩基和环烷基氨基嘧啶化合物、其组合物和用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| AU2003231231A1 (en) | 2002-05-06 | 2003-11-11 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
| BR0316680A (pt) | 2002-11-28 | 2005-10-18 | Schering Ag | Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| JP2006515014A (ja) | 2003-01-30 | 2006-05-18 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | ＰＫＣ−θのインヒビターとして有用な２，４−ジアミノピリミジン誘導体 |
| CA2564199A1 (en) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| MXPA06011890A (es) * | 2004-05-14 | 2006-12-14 | Pfizer Prod Inc | Derivados de pirimidina para tratar el crecimiento celular anomalo. |
-
2006
- 2006-12-11 JP JP2008546669A patent/JP4332590B2/ja not_active Expired - Fee Related
- 2006-12-11 ME MEP-09/08A patent/MEP0908A/xx unknown
- 2006-12-11 AP AP2008004488A patent/AP2008004488A0/xx unknown
- 2006-12-11 EA EA200801287A patent/EA014551B1/ru not_active IP Right Cessation
- 2006-12-11 CA CA2634646A patent/CA2634646C/en not_active Expired - Fee Related
- 2006-12-11 CN CN2006800487340A patent/CN101346380B/zh not_active Expired - Fee Related
- 2006-12-11 RS RSP-2008/0272A patent/RS20080272A/sr unknown
- 2006-12-11 EP EP06831737A patent/EP1966207A2/en not_active Withdrawn
- 2006-12-11 UA UAA200807169A patent/UA89123C2/ru unknown
- 2006-12-11 BR BRPI0620324-8A patent/BRPI0620324A2/pt not_active IP Right Cessation
- 2006-12-11 AU AU2006327871A patent/AU2006327871A1/en not_active Abandoned
- 2006-12-11 WO PCT/IB2006/003655 patent/WO2007072158A2/en active Application Filing
- 2006-12-11 KR KR1020087017637A patent/KR101060051B1/ko not_active IP Right Cessation
- 2006-12-14 NL NL2000375A patent/NL2000375C2/nl not_active IP Right Cessation
- 2006-12-19 DO DO2006000289A patent/DOP2006000289A/es unknown
- 2006-12-19 GT GT200600517A patent/GT200600517A/es unknown
- 2006-12-20 AR ARP060105660A patent/AR058399A1/es not_active Application Discontinuation
- 2006-12-20 PE PE2006001661A patent/PE20071138A1/es not_active Application Discontinuation
- 2006-12-20 HN HN2006042221A patent/HN2006042221A/es unknown
- 2006-12-20 TW TW095147907A patent/TW200736258A/zh unknown
- 2006-12-20 US US11/613,390 patent/US7820648B2/en not_active Expired - Fee Related
- 2006-12-21 UY UY30051A patent/UY30051A1/es not_active Application Discontinuation
-
2008
- 2008-05-19 IL IL191555A patent/IL191555A0/en unknown
- 2008-05-22 NO NO20082338A patent/NO20082338L/no not_active Application Discontinuation
- 2008-05-23 ZA ZA200804488A patent/ZA200804488B/xx unknown
- 2008-06-19 EC EC2008008563A patent/ECSP088563A/es unknown
- 2008-06-20 SV SV2008002969A patent/SV2008002969A/es not_active Application Discontinuation
- 2008-06-20 TN TNP2008000270A patent/TNSN08270A1/fr unknown
- 2008-06-20 CR CR10095A patent/CR10095A/es unknown
- 2008-06-20 MA MA31059A patent/MA30075B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR10095A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| HN2005000212A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| BRPI0607455A2 (pt) | composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica | |
| ECSP066406A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| ECSP099803A (es) | Derivados de bencimidazol | |
| BRPI0518459A2 (pt) | composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo | |
| AR053412A1 (es) | Compuestos inhibidores de la interaccion entre mdm2 y p53, un metodo de preparadcion, composicion farmaceutica y uso del compuesto para fabricar medicamentos | |
| DOP2009000248A (es) | Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal | |
| ECSP10010346A (es) | Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su síntesis | |
| MX2007013624A (es) | Inhibidores de proteina cinasa. | |
| UY29343A1 (es) | Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso. | |
| CR8749A (es) | Derivados de pirimidina para tratar el crecimiento celular anomalo | |
| ECSP078062A (es) | Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen | |
| UY29684A1 (es) | Derivados de piperidina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones | |
| DK1768945T3 (da) | Substituerede hydroxyacetophenon-derivater | |
| CU20080126A7 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| NI200500205A (es) | "derivados de pirimidina para el tratamiento del crecimiento celular anorma." | |
| UA93313C2 (en) | Benzimidazole derivatives | |
| UY28136A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| DOP2005000086A (es) | Derivados de pirimidina para tratar el crecimiento celular anomalo | |
| TH105256A (th) | อนุพันธ์ไพริมิดีนสำหรับการรักษาการเจริญเติบโตของเซล์ที่ผิดปกติ | |
| CU20080149A7 (es) | Composiciones fungicidas |